SGIOY:OTCMKTS
Shionogi 2 ADR Representing 1 Ord Shs
8,68 US$
arrow_downward
-0,23%(-0,020) 1 Д
8,68 US$
0,00% (0,00)
bedtimeПосле радног времена
Затворено: 12. окт, 16:00:00 GMT-4 · USD
search
Сви симболи
| Симбол | Цена | Промена | % промене |
|---|
insights_autoГенеришу се најзначајнији увиди за SGIOY...
Отвори
8,75 US$
Високо
8,75 US$
Ниско
8,47 US$
Трж. капитализација
2,49 бил.
Прос. количина
166,08 хиљ.
Количина
143,96 хиљ.
Највиша у 52 недеље
12,00 US$
Најнижа у 52 недеље
7,65 US$
Бета
0,07
Акцијски капитал
1,78 млрд.
Бр. запослених
6 хиљ.
Отвори
8,75 US$
Високо
8,75 US$
Ниско
8,47 US$
Трж. капитализација
2,49 бил.
Прос. количина
166,08 хиљ.
Количина
143,96 хиљ.
Највиша у 52 недеље
12,00 US$
Најнижа у 52 недеље
7,65 US$
Бета
0,07
Акцијски капитал
1,78 млрд.
Бр. запослених
6 хиљ.
Вести
Из веб-извора и од партнера за вести
Yahoo Finance
·
пре 3 дана
Can Shionogi (TSE:4507) Support Its Price With Earnings After IntraBio?
Профил
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
Shionogi 2 ADR Representing 1 Ord Shs – основни подаци
Главни извршни директорIsao Teshirogi
Запослени6,22 хиљ.
Основано1878
Седиште-
Сектор-
Веб-сајтshionogi.com